Investment Thesis
Entrada Therapeutics exhibits severe operational deterioration with revenue collapsing 87.9% YoY to just $25.4M while burning $128.5M in operating cash flow, indicating fundamental business model failure. Although the balance sheet remains intact with $90.4M cash and no debt, the unsustainable burn rate ($129.6M FCF negative) combined with negative 621% operating margins suggests cash runway constraints within 12-18 months without major strategic inflection.
Strengths
- Strong balance sheet with $306.1M stockholders equity and zero long-term debt
- Excellent liquidity position with 12.53x current ratio and $90.4M cash reserves
- No immediate debt maturity risk or covenant concerns
Risks
- Catastrophic 87.9% YoY revenue decline indicating failed commercialization or loss of major revenue stream
- Unsustainable cash burn of $128.5M in operating cash flow with only $25.4M in revenue
- Persistent operating losses of $157.9M with -621% operating margin suggesting inability to reach profitability in near-term
- Cash runway of approximately 8 quarters at current burn rate before balance sheet depletion
Key Metrics to Watch
- Quarterly revenue trends and pipeline catalysts - monitor for stabilization or inflection points
- Monthly cash burn rate and operating cash flow - critical for assessing runway extension
- Cost reduction initiatives and R&D spending - assess management's response to revenue collapse
Financial Metrics
Revenue
25.4M
Net Income
-143.8M
EPS (Diluted)
$-3.47
Free Cash Flow
-129.6M
Total Assets
377.4M
Cash
90.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-621.1%
Net Margin
-565.5%
ROE
-47.0%
ROA
-38.1%
FCF Margin
-509.6%
Balance Sheet & Liquidity
Current Ratio
12.53x
Quick Ratio
12.53x
Debt/Equity
0.00x
Debt/Assets
18.9%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-17T18:33:24.946071 |
Data as of: 2025-12-31 |
Powered by Claude AI